News & Views - Page 11 of 53 - Telix Pharmaceuticals Limited

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

Telix today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix’s investigational prostate cancer imaging agent, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the Nordic region.

Telix Completes Acquisition of Lightpoint Medical

Telix, today announces the completion of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business (refer to announcement on 21 June 2023).

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

Telix today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC).

Activities Report and Appendix 4C for the quarter ended 30 September 2023

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.

Telix Quarterly Results and Investor Call / Webcast Notification

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October 2023.

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated.

Telix Half-Year Results 2023 and Investor Call / Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August 2023.

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.

Telix Quarterly Results and Investor Call / Webcast Notification

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market close.

Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical

Telix today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals.